Melissa Magstadt, South Dakota Secretary of Health

South Dakota Department of Health Logo and button.

COVID-19 Vaccine Information

Everyone ages 5 and up is eligible for a FREE COVID-19 vaccine.
Get yours today!
Click for locations.


Vaccine Comparison Chart

Use the schedules below to determine how many total COVID-19 vaccine doses are recommended
based on primary series product, age, and immune status.

COVID-19 Vaccination Schedule for Most People.
People ages 6 months through 4 years - Moderna - Primary dose 1 and in 4-8 weeks primary dose 2 OR Pfizer-BioNTech - Primary Dose 1 and in 3-8 weeks Primary Dose 2 then in at least 8 weeks Primary Dose 3 
			  People ages 5-11 years - Moderna or Pfizer-BioNTech - Primary dose - then in 3-8 weeks (pfizer) or 4-8 weeks (Moderna) - at least 2 months later Bivalent mRND booster.
			  People ages 12 years and older - Moderna, Noravax, or Pfizer-BioNTech - Primary Dose 1 then Primary Dose 2 in 3-8 weeks (Norovax or Pfizer) OR in 4-8 weeks (Moderna) - In at least 2 months receive the Bivalent mRNA booster.
			  People ages 18 years and older who previously received the Janssen primary series dose - Primary dose - then in at least 2 months Bivalent mRNA booster.

COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised.
Moderna (ages 6 months-5 years) - Dose 1 (primary) - in 4 weeks, Dose 2 (primary) - in at least 4 weeks Dose 3 (primary).
Pfizer-BioNTech (ages 6 months to 4 years) - Dose 1 (primary) in 3 weeks Dose 2 (primary) in at least 8 weeks Dose 3 (primary).
Moderna or Pfizer-BoiNTech (ages 5-11 years) Dose 1 (primary) in 3 weeks (Pfizer) or in 4 weeks (Moderna) Dose 2 (primary) in at least 4 weeks, Dose 3 (primary) In at least 2 months, Bivalent mRNA booster.
Moderna or Pfizer-BioNTech (ages 12 years and older) - Dose 1 (primary) in 3 weeks (Pfizer) or 4 weeks (Moderna), Dose 2 (primary) - in at least 4 weeks, Dose 3 (primary) - in at least 2 months Dose 4 (Bivalent mRNA booster*)
			  OR Noravax - Primary dose then in 3 weeks dose 2 primary - then in at least 2 months Bivalent mRNA booster.

Janssen (ages 18 years and older)* - Dose 1 (primary) - in 4 weeks, Dose 2 (additional mRNA dose) - in at least 2 months, Dose 3 (bivalent mRNA booster*).

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

*For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† A monovalent Novovax booster dose may be used in limited situations in people 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable or unwilling to receive an mRNA vaccine. The monovalent Novavax booster dose is administered at least 6 months after completion of a primary series.

‡ Janssen COVID-19 Vaccine should only be used in certain limited situations. See:

Updated: December 20, 2022

For more specific clinical guidance, see:

General Vaccine Information

COVID-19 Vaccination Event Request Form!
To request COVID-19 vaccination assistance at your community organization or event, CLICK HERE! FREE Lyft Rides for COVID-19 Vaccine Appointments. Call 211 today to schedule your free Lyft ride.

  • Find providers offering the Bivalent COVID-19 Booster

  • 12/09/2022 - CDC Expands Updated COVID-19 Vaccines to Include Children Ages 6 Months through 5 Years

    • Following FDA action, today CDC expanded the use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years. Children ages 6 months through 5 years who previously completed a Moderna primary series are eligible to receive a Moderna bivalent booster 2 months after their final primary series dose. Children ages 6 months through 4 years who are currently completing a Pfizer primary series will receive a Pfizer bivalent vaccine as their third primary dose.

      Updated COVID-19 vaccines are formulated to protect against some of the more recently circulating viruses.

      Most importantly, COVID-19 vaccines are critical to providing ongoing protection as immunity wanes and the virus continues to mutate.

      The vast majority of children in this age group have not received any doses of a COVID-19 vaccine. CDC is working to increase parent and provider confidence in COVID-19 vaccines and improve uptake among the 95% of children who are not vaccinated or who have not completed the COVID-19 vaccine primary series. Parents should talk to their child’s health care provider to ensure their child is up to date on their COVID-19 and other vaccines.

  • - COVID-19 Public Education Materials

Vaccine Safety After Vaccination
Share via: